Urologie最新文献_第2页

Mitteilungen der DGU. DGU通讯。

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 DOI: 10.1007/s00120-026-02823-6

引用次数: 0

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 DOI: 10.1007/s00120-026-02825-4

引用次数: 0

[Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer]. [聚（adp -核糖）聚合酶抑制剂联合治疗转移性去势抵抗性前列腺癌]。

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 Epub Date: 2025-12-16 DOI: 10.1007/s00120-025-02747-7

Carsten Ohlmann, Christian Gratzke, Laura-Maria Krabbe

{"title":"[Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer].","authors":"Carsten Ohlmann, Christian Gratzke, Laura-Maria Krabbe","doi":"10.1007/s00120-025-02747-7","DOIUrl":"10.1007/s00120-025-02747-7","url":null,"abstract":"Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge. Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) combined with new hormonal agents (NHA) offer novel treatment options.Objective: This review summarizes the current status of PARPi + NHA combination therapy in mCRPC.Materials and methods: Summary of relevant phase II and III trials on PARPi + NHA and the G‑BA (Gemeinsame Bundesausschuss) decision as well as the current S3 guideline recommendations.Results: PARPi + NHA demonstrated improved efficacy compared to NHA alone in an all-comers population that received prior androgen deprivation therapy (ADT) or docetaxel therapy. In particular the subgroup of patients with homologous recombination repair (HRR) and breast cancer (BRCA) 1/2 mutations had the best outcomes. Olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone are approved combinations, expanding treatment options in mCRPC.Conclusion: PARPi + NHA represent a significant advance in mCRPC therapy. Molecular genetic testing for HRR mutations, especially BRCA 1/2, is crucial for treatment planning.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"521-529"},"PeriodicalIF":0.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Termine. Termine。

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 DOI: 10.1007/s00120-026-02824-5

引用次数: 0

GeSRU.

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 Epub Date: 2026-04-29 DOI: 10.1007/s00120-026-02832-5

引用次数: 0

AUO.

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 DOI: 10.1007/s00120-026-02822-7

引用次数: 0

[Penile cancer: management strategies for patients with lymph node involvement : A systematic review]. [阴茎癌：淋巴结受累患者的治疗策略：系统综述]。

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 Epub Date: 2026-03-23 DOI: 10.1007/s00120-026-02813-8

Desiree Louise Dräger

引用次数: 0

[Influence of MRI fusion biopsy on treatment recommendations : How reliable are biopsy results?] MRI融合活检对治疗建议的影响：活检结果有多可靠？］

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 Epub Date: 2025-12-09 DOI: 10.1007/s00120-025-02738-8

P Schildhauer, M Müller, A S Merseburger, S M Weiler, A Fürschke, Y Elser, A Moderegger, H E Fender

{"title":"[Influence of MRI fusion biopsy on treatment recommendations : How reliable are biopsy results?]","authors":"P Schildhauer, M Müller, A S Merseburger, S M Weiler, A Fürschke, Y Elser, A Moderegger, H E Fender","doi":"10.1007/s00120-025-02738-8","DOIUrl":"10.1007/s00120-025-02738-8","url":null,"abstract":"Background: The detection of clinically significant prostate cancer remains a diagnostic challenge. The combination of magnetic resonance imaging (MRI) fusion biopsy and systematic biopsy is currently considered standard in primary diagnostics.Objectives: The study examined differences in guideline-based treatment recommendations derived from the histology of MRI fusion versus systematic biopsy and their concordance with prostatectomy histology.Materials and methods: A total of 476 patients who underwent prostate biopsy between January 2022 and December 2024 were included. Primary endpoints were histological classification by biopsy method and the resulting treatment recommendations. In a subgroup of 57 patients (115 lesions) who underwent radical prostatectomy, concordance between biopsy and surgical histology was analyzed based on Prostate Imaging Reporting and Data System (PI-RADS) scores. Statistical analyses included binomial test, McNemar's test, Cohen's κ, and binary logistic regression (significance level p < 0.05).Results: The combined approach detected significantly more clinically relevant cancers than systematic biopsy alone (41.7% vs. 27.9%; p < 0.001) and led to more curative treatment recommendations (36.0% vs. 26.2%; p < 0.001). Compared with MRI fusion biopsy alone, it also yielded a higher rate of curative recommendations (36.0% vs. 32.8%; p < 0.001). Concordance of Gleason scores with prostatectomy findings was highest for PI-RADS 5 lesions (κ = 0.294) and significantly higher than for PI-RADS 3 (p = 0.029).Conclusion: The combined biopsy approach increases the rate of guideline-concordant curative treatment recommendations. However, the added diagnostic value of systematic biopsy remains limited. Higher concordance between biopsy and prostatectomy histology was observed only in PI-RADS 5 lesions.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"513-520"},"PeriodicalIF":0.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145709575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Berufspolitik BvDU. Berufspolitik BvDU .

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 DOI: 10.1007/s00120-026-02826-3

引用次数: 0

[At-home tests in the healthcare market-opportunities, limitations, and clear oversight using the example of PSA home testing]. 【家庭检测在医疗保健市场中的机遇、局限性和明确的监管（以PSA家庭检测为例）】。

IF 0.4 4区医学

Urologie Pub Date : 2026-05-01 Epub Date: 2026-04-09 DOI: 10.1007/s00120-026-02814-7

Sulafah El-Khadra

{"title":"[At-home tests in the healthcare market-opportunities, limitations, and clear oversight using the example of PSA home testing].","authors":"Sulafah El-Khadra","doi":"10.1007/s00120-026-02814-7","DOIUrl":"10.1007/s00120-026-02814-7","url":null,"abstract":"Mobile health tests are gaining increasing relevance in healthcare systems and address existing gaps in care, including low participation in preventive screening, access barriers, and the growing demand for patient autonomy in health management. In particular, home-based tests, such as those measuring prostate-specific antigen (PSA), offer low-threshold access to preventive care and may serve as an entry point into the medical care pathway.From a urological perspective, however, these potentials are clearly limited. Self-tests provide only isolated measurements and do not replace medical diagnostics or clinical evaluation. Especially in the context of PSA testing, there is a significant risk of misinterpretation: both false-positive results, leading to unnecessary diagnostic cascades, and false-negative findings, creating false reassurance, may compromise patient safety.Key challenges also include pre-analytical limitations, the absence of structured indication, and insufficient integration into established care pathways. Patients are often left alone with potentially critical results, both organizationally and emotionally. Regulatory approval ensures minimum safety standards but does not substitute for structured, quality-assured medical process management.The German Professional Association of Urology (BvDU) critically assesses PSA home testing without mandatory medical involvement. In urology, PSA is not an isolated screening parameter but part of a complex, risk-adapted diagnostic pathway.Home testing is therefore only justifiable if it is systematically integrated into structured, physician-led care pathways. This includes adequate patient information, appropriate indication, professional interpretation of results, and ensured follow-up in case of abnormal findings.In conclusion, mobile tests may represent a valuable access point to healthcare; however, they must not replace medical responsibility. Patient safety must take precedence over market dynamics.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"537-541"},"PeriodicalIF":0.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0